Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.66 Billion KRW | 5980.93% |
| 2022 | -28.28 Million KRW | 99.47% |
| 2021 | -5.34 Billion KRW | -498.84% |
| 2020 | 1.34 Billion KRW | 70.5% |
| 2019 | 786.25 Million KRW | 109.18% |
| 2018 | -8.56 Billion KRW | -576.06% |
| 2017 | -1.26 Billion KRW | -242.86% |
| 2016 | 886.6 Million KRW | 50.69% |
| 2015 | 588.36 Million KRW | 105.26% |
| 2014 | -11.18 Billion KRW | -241.1% |
| 2013 | 7.93 Billion KRW | 373.47% |
| 2012 | -2.89 Billion KRW | 57.22% |
| 2011 | -6.77 Billion KRW | -431.59% |
| 2010 | 2.04 Billion KRW | -71.06% |
| 2009 | 7.06 Billion KRW | 304.0% |
| 2008 | 1.74 Billion KRW | -68.44% |
| 2007 | 5.53 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 350.31 Million KRW | 120.1% |
| 2024 Q1 | -1.74 Billion KRW | -294.89% |
| 2023 FY | 1.66 Billion KRW | 5980.93% |
| 2023 Q4 | 894.11 Million KRW | 236.08% |
| 2023 Q2 | 719.05 Million KRW | 1.65% |
| 2023 Q1 | 707.41 Million KRW | -61.35% |
| 2023 Q3 | -657.04 Million KRW | -191.38% |
| 2022 Q4 | 1.83 Billion KRW | 195.31% |
| 2022 FY | -28.28 Million KRW | 99.47% |
| 2022 Q2 | -274.1 Million KRW | -181.63% |
| 2022 Q3 | -1.92 Billion KRW | -600.64% |
| 2022 Q1 | 335.8 Million KRW | 110.73% |
| 2021 Q2 | -1.15 Billion KRW | -289.55% |
| 2021 Q3 | -1.67 Billion KRW | -44.93% |
| 2021 Q1 | 608.43 Million KRW | 211.63% |
| 2021 FY | -5.34 Billion KRW | -498.84% |
| 2021 Q4 | -3.13 Billion KRW | -87.28% |
| 2020 Q3 | -236.89 Million KRW | -177.5% |
| 2020 FY | 1.34 Billion KRW | 70.5% |
| 2020 Q1 | 1.81 Billion KRW | 292.15% |
| 2020 Q2 | 305.66 Million KRW | -83.18% |
| 2020 Q4 | -545.04 Million KRW | -130.08% |
| 2019 Q3 | -447.59 Million KRW | -144.53% |
| 2019 Q4 | -945.55 Million KRW | -111.25% |
| 2019 Q2 | 1 Billion KRW | -14.4% |
| 2019 Q1 | 1.17 Billion KRW | 139.37% |
| 2019 FY | 786.25 Million KRW | 109.18% |
| 2018 Q3 | -2.56 Billion KRW | -22.87% |
| 2018 FY | -8.56 Billion KRW | -576.06% |
| 2018 Q4 | -2.98 Billion KRW | -16.28% |
| 2018 Q2 | -2.08 Billion KRW | -125.17% |
| 2018 Q1 | -927.18 Million KRW | -323.17% |
| 2017 FY | -1.26 Billion KRW | -242.86% |
| 2017 Q3 | -2 Billion KRW | -616.99% |
| 2017 Q4 | 415.46 Million KRW | 120.71% |
| 2017 Q2 | -279.72 Million KRW | -146.36% |
| 2017 Q1 | 603.32 Million KRW | 143.48% |
| 2016 Q1 | 542.41 Million KRW | 263.13% |
| 2016 Q4 | 247.78 Million KRW | -24.22% |
| 2016 FY | 886.6 Million KRW | 50.69% |
| 2016 Q3 | 326.96 Million KRW | 241.81% |
| 2016 Q2 | -230.56 Million KRW | -142.51% |
| 2015 Q1 | 577.92 Million KRW | 114.79% |
| 2015 Q4 | -332.51 Million KRW | -306.73% |
| 2015 Q3 | 160.84 Million KRW | -11.68% |
| 2015 Q2 | 182.12 Million KRW | -68.49% |
| 2015 FY | 588.36 Million KRW | 105.26% |
| 2014 Q3 | -3.02 Billion KRW | 20.99% |
| 2014 Q4 | -3.9 Billion KRW | -29.2% |
| 2014 FY | -11.18 Billion KRW | -241.1% |
| 2014 Q1 | -432.95 Million KRW | -105.14% |
| 2014 Q2 | -3.82 Billion KRW | -783.83% |
| 2013 Q4 | 8.43 Billion KRW | 1578.05% |
| 2013 Q1 | 306.25 Million KRW | 120.04% |
| 2013 Q2 | -237.01 Million KRW | -177.39% |
| 2013 FY | 7.93 Billion KRW | 373.47% |
| 2013 Q3 | -570.42 Million KRW | -140.67% |
| 2012 Q3 | 138.15 Million KRW | 140.74% |
| 2012 Q4 | -1.52 Billion KRW | -1206.16% |
| 2012 FY | -2.89 Billion KRW | 57.22% |
| 2012 Q1 | 573.14 Million KRW | 0.0% |
| 2012 Q2 | -339.09 Million KRW | -159.16% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | -6.77 Billion KRW | -431.59% |
| 2011 Q3 | -953.44 Million KRW | 33.3% |
| 2011 Q2 | -1.42 Billion KRW | -156.83% |
| 2011 Q1 | 2.51 Billion KRW | 204.4% |
| 2010 FY | 2.04 Billion KRW | -71.06% |
| 2010 Q3 | -417.21 Million KRW | -130.9% |
| 2010 Q4 | 826.38 Million KRW | 298.07% |
| 2010 Q2 | 1.35 Billion KRW | 374.12% |
| 2010 Q1 | 284.8 Million KRW | 115.19% |
| 2009 Q4 | -1.87 Billion KRW | -116.71% |
| 2009 Q1 | -652.11 Million KRW | 78.39% |
| 2009 Q3 | 11.22 Billion KRW | 787.95% |
| 2009 Q2 | -1.63 Billion KRW | -150.15% |
| 2009 FY | 7.06 Billion KRW | 304.0% |
| 2008 Q1 | 3.5 Billion KRW | 221.28% |
| 2008 Q3 | -690.97 Million KRW | -135.46% |
| 2008 FY | 1.74 Billion KRW | -68.44% |
| 2008 Q2 | 1.94 Billion KRW | -44.46% |
| 2008 Q4 | -3.01 Billion KRW | -336.73% |
| 2007 Q1 | 3.48 Billion KRW | 0.0% |
| 2007 Q2 | 2.63 Billion KRW | -24.42% |
| 2007 Q3 | 1.74 Billion KRW | -33.75% |
| 2007 FY | 5.53 Billion KRW | 0.0% |
| 2007 Q4 | -2.89 Billion KRW | -265.83% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 123.166% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 97.131% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 102.792% |
| HANDOK Inc. | -28.79 Billion KRW | 105.777% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 119.768% |
| Yuhan Corporation | 93.5 Billion KRW | 98.221% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 85.043% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 106.705% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 98.862% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 52.587% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 166.371% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 180.213% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 136.765% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 92.551% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 123.166% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 107.944% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 53.576% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 101.407% |
| JW Holdings Corporation | 19.02 Billion KRW | 91.257% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 102.108% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 99.217% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 95.505% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 102.902% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 72.826% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 66.761% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 123.166% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 95.5% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 98.508% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 95.505% |
| Yuhan Corporation | 93.5 Billion KRW | 98.221% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 110.237% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 142.924% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 72.815% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 95.505% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 91.201% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 96.553% |
| CKD Bio Corp. | -24.19 Billion KRW | 106.876% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 93.045% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 93.937% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 94.413% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 102.902% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 96.461% |
| Boryung Corporation | 40.2 Billion KRW | 95.862% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 105.31% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 166.371% |
| JW Lifescience Corporation | 28.14 Billion KRW | 94.089% |